Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
To accelerate the development of next-generation radioconjugates to treat cancer
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
Venus Remedies' manufacturing unit, located in Baddi, Himachal Pradesh, has been recommended for supplying cephalosporin dry powder to UNICEF
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
It is the first autotaxin inhibitor to be investigated in cancer patients
Subscribe To Our Newsletter & Stay Updated
